Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication

(2017) Soichiro Sue et al.   INTERNAL MEDICINE

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy

(2017) Kouichi Sakurai et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

(2016) T. Kagami et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

(2016) Sho Suzuki et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis

(2016) Yiqiao Xin et al.   BMC GASTROENTEROLOGY

Gastroesophageal Reflux Disease in Time Covering Eradication for All Patients Infected with Helicobacter pylori in Japan

(2016) Mitsushige Sugimoto et al.   DIGESTION

Trends in Gastrointestinal Diseases in Japan

(2016) Yasuhisa Shinomura   DIGESTION

Key Issues Associated with Helicobacter pylori Eradication

(2016) Takashi Kawai et al.   DIGESTION

A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori

(2016) Masahiro Tsujimae et al.   DIGESTION

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes

(2016) Tadayoshi Okimoto et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Vonoprazanversusconventional proton pump inhibitor-based triple therapy as first-line treatment againstHelicobacter pylori: A multicenter retrospective study in clinical practice

(2016) Satoki Shichijo et al.   Journal of Digestive Diseases

A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori

(2016)   Journal of Gastrointestinal and Liver Diseases

Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori

(2016) Satoshi Shinozaki et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication

(2016) Yusaku Kajihara et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker

(2016) Hitomi Yamasaki et al.   XENOBIOTICA

Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Antimicrobial Resistance and Characteristics of Eradication Therapy ofHelicobacter pyloriin Japan: A Multi-Generational Comparison

(2014) Takuma Okamura et al.   HELICOBACTER

Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy

(2013) L. Gatta et al.   BMJ-British Medical Journal

The effects of varying acidity onHelicobacter pylorigrowth and the bactericidal efficacy of ampicillin

(2012) E. A. Marcus et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

(2012) A. G. McNicholl et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

A new approach for elimination of gastric cancer deaths in Japan

(2012) Masahiro Asaka   INTERNATIONAL JOURNAL OF CANCER

Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough

(2011) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in Japan

(2011) Toshio Fujioka et al.   JOURNAL OF GASTROENTEROLOGY

Helicobacter pylorieradication therapy

(2010) Hidekazu Suzuki et al.   Future Microbiology

Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition

(2010) Masahiro Asaka et al.   HELICOBACTER

Helicobacter pyloriInfection

(2010) Kenneth E.L. McColl   NEW ENGLAND JOURNAL OF MEDICINE

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial

(2008) Kazutoshi Fukase et al.   LANCET

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology